Clinical Trials Browser

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT07522697 2026-04-13

MITO END-4

Phase 2 Not yet recruiting

48 enrolled

Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Phase 2 Unknown

9 enrolled

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01276379 2021-07-02

POSIBA

Phase 2 Completed

221 enrolled 17 charts

Gastrointestinal

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Phase 2 Terminated

3 enrolled 2 charts

Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01640444 2019-04-11

VISNU-2

Phase 2 Completed

240 enrolled

Gastrointestinal

Neoplastic Cells, Circulating, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT02644122 2018-07-11

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Phase 2 Terminated

1 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

MITO END-4

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

SAFIR-PI3K

POSIBA

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

VISNU-2

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes